GPRC6A: Jack of all metabolism (or master of none)

Background: GPRC6A, a widely expressed G-protein coupled receptor, is proposed to be a master regulator of complex endocrine networks and metabolic processes. GPRC6A is activated by multiple ligands, including osteocalcin (Ocn), testosterone (T), basic amino acids, and various cations. Scope of Revi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Min Pi (Författare, medförfattare), Satoru Kenneth Nishimoto (Författare, medförfattare), L. Darryl Quarles (Författare, medförfattare)
Materialtyp: Bok
Publicerad: Elsevier, 2017-02-01T00:00:00Z.
Ämnen:
Länkar:Connect to this object online.
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f354a9fb1b724a8b80e2870fc0fbd895
042 |a dc 
100 1 0 |a Min Pi  |e author 
700 1 0 |a Satoru Kenneth Nishimoto  |e author 
700 1 0 |a L. Darryl Quarles  |e author 
245 0 0 |a GPRC6A: Jack of all metabolism (or master of none) 
260 |b Elsevier,   |c 2017-02-01T00:00:00Z. 
500 |a 2212-8778 
500 |a 10.1016/j.molmet.2016.12.006 
520 |a Background: GPRC6A, a widely expressed G-protein coupled receptor, is proposed to be a master regulator of complex endocrine networks and metabolic processes. GPRC6A is activated by multiple ligands, including osteocalcin (Ocn), testosterone (T), basic amino acids, and various cations. Scope of Review: We review the controversy surrounding GPRC6A functions. In mice, GPRC6A is proposed to integrate metabolic functions through the coordinated secretion of hormones, including insulin, GLP-1, T, and IL-6, and direct effects of this receptor to control glucose and fat metabolism in the liver, skeletal muscle, and fat. Loss-of-GPRC6A results in metabolic syndrome (MetS), and activation of GPRC6A stimulates proliferation of β-cells, increases peripheral insulin sensitivity, and protects against high fat diet (HFD) induced metabolic abnormalities in most mouse models. Bone, cardiovascular, immune, and skin functions of GPRC6A have also been identified in mice. Expression of GPRC6A is increased in prostate cancer (PCa) cells, and inhibition of GPRC6A attenuates PCa progression in mouse models. The function of GPRC6A in humans, however, is not clear. During evolution, a unique polymorphism of GPRC6A emerged mainly in humans of Asian and European decent that has been proposed to alter membrane trafficking and function. In contrast, the ancestral allele found in all other species is retained in 1%, 15%, and 40% of people of Asian, European and African descent, respectively, suggesting GPRC6A gene variants may contribute to the racial disparities in the risk of developing MetS and PCa. Major Conclusions: If the regulatory functions of GPRC6A identified in mice translate to humans, and polymorphisms in GPRC6A are found to predict racial disparities in human diseases, GPRC6A may be a new gene target to predict, prevent, and treat MetS, PCa, and other disorders impacted by GPRC6A. Keywords: GPCR, Racial disparities, Prostate cancer, Type 2 diabetes, Membrane trafficking, Osteocalcin, Testosterone, Gene polymorphisms 
546 |a EN 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Molecular Metabolism, Vol 6, Iss 2, Pp 185-193 (2017) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2212877816302927 
787 0 |n https://doaj.org/toc/2212-8778 
856 4 1 |u https://doaj.org/article/f354a9fb1b724a8b80e2870fc0fbd895  |z Connect to this object online.